Longeveron Stem Cell Therapy Improves Frailty Condition

Phase 2b trial shows laromestrocel increased 6-minute walk test distance in frailty patients

Published on Feb. 25, 2026

Got story updates? Submit your updates here. ›

Longeveron Inc. announced that results of its Phase 2b clinical trial of laromestrocel, a mesenchymal stem cell product, were published in Cell Stem Cell. The trial demonstrated that laromestrocel improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo. The treatment resulted in clinically meaningful, dose-and time-dependent increases in the 6-minute walk test distance.

Why it matters

Age-related frailty is a major public health issue, as those with frailty are disproportionately compromised in their ability to cope with everyday and acute stressors, are at high vulnerability to disease and injury, and are at increased risk for poor outcomes and death after surgery. The positive results from this stem cell therapy trial suggest a potential new treatment approach for managing frailty.

The details

The Phase 2b, randomized, dose-finding clinical trial evaluated whether laromestrocel, human bone marrow-derived allogeneic mesenchymal stem cells, improves physical functioning and patient self-reported outcomes in 148 ambulatory individuals with frailty. Laromestrocel infusions resulted in clinically meaningful, dose-and time-dependent increases in the primary endpoint of the 6-minute walk test compared with placebo, as well as increased 6MWT distance correlating with improved PROMIS Physical Function score. Increasing doses of laromestrocel were also associated with decreases in a potential biomarker for laromestrocel responsiveness.

  • The Phase 2b clinical trial results were published on February 25, 2026.

The players

Longeveron Inc.

A clinical stage biotechnology company developing regenerative medicines, including the laromestrocel stem cell therapy product.

Joshua M. Hare, MD, FACC, FAHA

Chief Science Officer at Longeveron.

Got photos? Submit your photos here. ›

What they’re saying

“We are highly encouraged by these Phase 2b results that demonstrate the potential of stem cell therapy to improve the condition of patients with aging-related frailty.”

— Joshua M. Hare, MD, FACC, FAHA, Chief Science Officer (Longeveron)

What’s next

Longeveron plans to continue evaluating laromestrocel in further clinical trials for the management of frailty and other age-related conditions.

The takeaway

This stem cell therapy trial represents a promising new approach to addressing the significant public health challenge of age-related frailty, which can lead to serious health consequences and poor outcomes. If further developed, laromestrocel could provide a new treatment option to improve physical function and quality of life for frail older adults.